Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 501 - 550 out of 118,886

Document Document Title
WO/2016/094850A1
The invention includes a composition comprising an astrocyte comprising aligned and elongated astrocyte processes resulting from ex vivo machine-driven, physical stretching of the astrocyte maintained in culture, as well as a method of m...  
WO/2016/091079A1
The present invention relates to donepezil derivatives of general formula (I) or pharmaceutically acceptable salts thereof, wherein R is described in the specification; preparation methods therefor and compositions comprising an effectiv...  
WO/2016/090495A1
The present invention is related to a compound that includes (a) α-L-iduronidase (IDUA), a fragment, or analog thereof and (b) a dendrimeric targeting moiety, for example, a dendrimeric targeting moiety including Angiopep-2. In certain ...  
WO/2016/092042A1
The present invention relates to a pharmaceutical combination comprising a first active ingredient which is (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2- ([Z]- propylimino)-3-o-tolyl-thiazolidin-4-one or a pharmaceutically...  
WO/2016/093515A1
Disclosed in the present specification is a composition for activating any one or more genes of an XPD gene, a Klotho gene, a Sirt-1 gene, an ERCC8 gene and a FoxO3 gene, the composition containing catechin comprising a methyl group, a s...  
WO/2016/092878A1
[Problem] To enable the easy mass production of an ether phospholipid having superior therapeutic and ameliorating effects on cranial nerve diseases such as Alzheimer's disease, Parkinson's disease, depression and schizophrenia, metaboli...  
WO/2016/094659A1
A compound of Formula II, or a salt, ester, solvate, hydrate or prodrug thereof: where: X1 is a branched or unbranched C1-10 alkyl, (CH2)s-NH-(CH2)t, (CH2)s-0-(CH2)t, or (CH2)S-C(NH2)- (CH2)v-NH-(CH2)t,where s, t and v are each, independ...  
WO/2016/092539A1
The present invention discloses a composition comprising a therapeutically effective amount of Tetrahydrocannabinol (THC) or a derivative thereof, or Cannabidiol (CBD) or a derivative thereof, or a combination thereof for use in relievin...  
WO/2016/094566A3
The present invention relates to antibodies that bind to receptors expressed on the blood brain barrier and methods of using the same.  
WO/2016/092479A1
The invention relates to a stable oral liquid formulation developed for treating negative effects of Advanced Glycation end Products (AGEs) in a clear oral liquid formulation containing Resveratrol, Benfotiamine, Pyridoxamine and one or ...  
WO/2016/094881A2
The disclosure provides binding proteins that specifically bind to LRP-8 and optionally cross the blood brain barrier (BBB), localize to the brain and/or localize to the spinal cord.  
WO/2016/092459A1
The invention provides compositions and methods for treatment of epilepsy in an animal. In one embodiment, a dietary regime suitable for enhancing the effect of an anti-epileptic drug (AED) in an animal can comprise a food composition co...  
WO/2016/094881A3
The disclosure provides binding proteins that specifically bind to LRP-8 and optionally cross the blood brain barrier (BBB), localize to the brain and/or localize to the spinal cord.  
WO/2016/094566A2
The present invention relates to antibodies that bind to receptors expressed on the blood brain barrier and methods of using the same.  
WO/2016/092865A1
Provided is an antibody or an immunologically reactive fragment thereof which targets exclusively an Aβ having a specific turn structure of Aβ (a toxic conformer of Aβ). Also provided are a medicinal composition comprising, as an acti...  
WO/2016/093342A1
Compounds represented by formula (I) or pharmaceutically-acceptable salts thereof. (The symbols in formula [I] are as defined in the description.)  
WO/2016/092002A1
The present invention relates to novel 1,2,4-triazolo[4,3-a]pyridine compounds of formula (I) as positive allosteric modulators (PAMs) of the metabotropic glutamate receptor subtype 2 ("mGluR2"). The invention is also directed to pharmac...  
WO/2016/091776A1
The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said co...  
WO/2016/091996A1
The present invention relates to a dosing regimen for (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2- ([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one.  
WO/2016/092453A1
The invention relates to prevention, treatment and slowing the progression of brain pathology in a disease or condition associated with ApoE4 genotype such as Alzheimer's Disease (AD) in a subject having the ApoE4 genotype through activa...  
WO/2016/090299A1
The present disclosure relates to certain amine derivatives of fused bicyclic heterocycles that inhibit the amine reuptake function of the biogenic amine transporters, dopamine transporter (DAT), serotonin transporter (SERT) and norepine...  
WO/2016/086320A1
Provided herein are antigen-binding constructs such as antibodies that bind to the RRM-1 domain of TDP-43. The antigen-binding constructs are capable of blocking the interaction of TDP-43 with NF-κB in cells. Also provided herein are me...  
WO/2016/088125A1
This disclosure relates to compositions for use in treatment of Alzheimer's Disease, and/or a ocular and retinal degenerative disease, such as age related macular degeneration. The described compositions include effective amounts of LLMe...  
WO/2016/087771A1
The invention relates to a compound of formula (Ia) for the use thereof in the treatment or prevention of diseases relating to the instability of mitochondrial DNA.  
WO/2016/088132A1
The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an ef...  
WO/2016/089648A1
The disclosure provides pharmaceutical compositions comprising Bach1 Inhibitors and Nrf2 Activators. The disclosure also provides methods of treating diseases such as psoriasis, multiple sclerosis, and COPD comprising administering a Bac...  
WO/2016/090380A1
The present invention relates to novel PDE2 inhibitory compounds of Formula I as described above, their use as pharmaceuticals and pharmaceutical compositions comprising them.  
WO/2016/090296A1
The present disclosure relates to certain amine derivatives of fused bicyclic heterocycles that inhibit the amine reuptake function of the biogenic amine transporters, dopamine transporter (DAT), serotonin transporter (SERT) and norepine...  
WO/2016/086261A1
The present invention relates to compounds of the formula I or II: (I) (II) processes for their preparation and their use as pharmaceutical agents or compositions in the treatment, of neurological disorders.  
WO/2016/088838A1
The present invention provides a compound having a novel P2X3 and/or P2X2/3 receptor antagonizing effect. A compound represented by formula (I): (in the formula, R1a is an optionally substituted alkyl or the like, R1b is a hydrogen atom ...  
WO/2016/089893A1
The present invention relates to pharmaceutical compositions of an non-steroidal anti- inflammatory drug (NSAIDs) such as, aspirin, diclofenac, ibuprofen, ketoprofen, or naproxen, or any pharmaceutically acceptable salts, solvates, or pr...  
WO/2016/090251A1
The present disclosure provides a method of treating seizure in a subject having aberrant alkaline phosphatase activities, comprising administering a therapeutically effective amount of at least one recombinant alkaline phosphatase to th...  
WO/2016/088797A1
Provided are: a nucleic acid that reduces toxicity caused by abnormal accumulation of an RNA-binding protein in cells and is usable for preventing or treating a neurodegenerative disease; and a prophylactic or therapeutic agent for a neu...  
WO/2016/089187A1
The present invention relates to: a cyclic peptide (cyclo [Cys-Gln-Arg-Pro-Pro-Arg-Cys] peptide) composed of the amino acid sequence of SEQ ID NO: 2; and a composition for apoptotic cell detection, drug delivery and imaging, containing t...  
WO/2016/089766A1
The disclosure provides a novel polymorph of Compound (I):, 2-((l-(2-(4-Fluorophenyl)-2-oxoethyl)piperidin-4- yl)methyl)isoindolin-l-one monohydrochloride dihydrate, i.e., Form (A) of Compound (Ι)·ΗΟ·2Η2O. Pharmaceutical compositio...  
WO/2016/088816A1
Provided are: a compact-sized granulate of zinc acetate hydrate, in which the loss of crystallization water is suppressed during a manufacturing process by controlling the material temperature of the granulate to lower than 40°C during ...  
WO/2016/088132A9
The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an ef...  
WO/2016/087489A1
The present invention relates to novel, selective, radiolabelled mGluR2 ligands which are useful for imaging and quantifying the metabotropic glutamate receptor mGluR2 in tissues, using positron-emission tomography (PET). The invention i...  
WO/2016/086357A1
Provided are methyl oxazole piperidine compounds, which are antagonists of orexin receptors, and compositions thereof. Provided are also methods for treatment or prevention of neurological and psychiatric disorders and diseases in which ...  
WO/2016/089304A1
The present invention provides a method of treating one or more sodium channel related diseases or disorders in an individual, including related symptoms. The method comprises administering to the individual a tetrahydropyridine derivati...  
WO/2016/090316A1
Disclosed is a composition suitable for oral administration and capable of treating individuals suffering from unipolar disorder, bipolar disorder and/or bipolar disorder with an unhealthy body weight. The composition comprises a combina...  
WO/2016/089997A1
The present invention provides methods of preventing and/or reducing risk of neurodegeneration of association cortex, and/or inhibiting or reversing formation of phosphorylated tau or COXIV in the prefrontal cortex of a mammal in need th...  
WO/2016/090317A1
Herein, compounds of formula (I), compositions and methods for modulating inclusion formation and stress granules in cells related to the onset of neurodegenerative diseases, musculoskeletal diseases, cancer, ophthalmological diseases, a...  
WO/2016/090230A1
The invention relates to HDAC inhibitors for the treatment of peripheral neuropathy in a subject in need thereof. Also provided herein are methods for treating peripheral neuropathy in a subject in need thereof comprising administering t...  
WO/2016/087487A1
The present invention relates to novel 6,7-dihydropyrazolo[1,5-α]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 ("mGluR2"). The invention is also directed to pharm...  
WO/2016/088834A1
A compound shown by general formula (I) (in the formula, all of the symbols are as defined in the specification) has selective S1P5 receptor agonist activity due to having a linker from a phenyl group to a cyclic substituent in a dihydro...  
WO/2016/086358A1
Provided are hydroxymethyl piperidine compounds, which are antagonists of orexin receptors, and compositions thereof. Provided are also methods for treatment or prevention of neurological and psychiatric disorders and diseases in which o...  
WO/2016/087429A1
The present invention relates to specific dosages of an A2A antagonist for use as a medicament and in particular useful for the treatment of Parkinson Disease and Attention Deficit/Hyperactivity Disorder.  
WO/2016/088813A1
Provided are: a compound having an antagonistic activity on an orexin receptor, a pharmaceutically acceptable salt of the compound, or a solvate of the compound or the pharmaceutically acceptable salt; a pharmaceutical composition charac...  
WO/2016/090154A1
Provided herein are methods of treating multiple sclerosis with dimethyl fumarate using an up-titration regimen. The methods provided herein are to reduce dimethyl fumarate-related gastro-intestinal adverse events in multiple sclerosis p...  

Matches 501 - 550 out of 118,886